Covestor
SNDX icon

Covestor’s Syndax Pharmaceuticals SNDX Stock Holding History

Covestor’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1K Buy
37
+8
+28% +$162 ﹤0.01% 2203
2026
Q2 		$1K Buy
29
+21
+263% +$437 ﹤0.01% 2332
2026
Q1 		$0 Hold
8
– – ﹤0.01% 2730
2025
Q4 		$0 Hold
8
– – ﹤0.01% 2699
2025
Q3 		$0 Sell
8
-29
-78% -$380 ﹤0.01% 2729
2025
Q2 		$0 Buy
37
+28
+311% +$308 ﹤0.01% 2715
2025
Q1 		$0 Buy
9
+4
+80% +$56 ﹤0.01% 2690
2024
Q4 		$0 Buy
5
+1
+25% +$17 ﹤0.01% 2695
2024
Q3 		$0 Sell
4
-1
-20% -$21 ﹤0.01% 2718
2024
Q2 		$0 Hold
5
– – ﹤0.01% 2710
2024
Q1 		$0 Hold
5
– – ﹤0.01% 2693
2023
Q4 		$0 Sell
5
-1
-17% -$15 ﹤0.01% 2672
2023
Q3 		$0 Hold
6
– – ﹤0.01% 2665
2023
Q2 		$0 Sell
6
-13
-68% -$271 ﹤0.01% 2605
2023
Q1 		$0 Buy
19
+5
+36% +$124 ﹤0.01% 2538
2022
Q4 		$0 Sell
14
-1
-7% -$23 ﹤0.01% 2561
2022
Q3 		$0 Buy
15
+3
+25% +$67 ﹤0.01% 2554
2022
Q2 		$0 Buy
+12
New +$200 ﹤0.01% 2336

Other funds holding SNDX

State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $474B AUM 32.39% 1-Year Est. Return
Candriam SCA
Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $77.1B AUM 11.99% 1-Year Est. Return
Aisling Capital Management
Aisling Capital Management New York $299M AUM 39.78% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $60.6B AUM 33.98% 1-Year Est. Return

Covestor's SNDX Position: Q3 2026 in Review

Covestor increased its Syndax Pharmaceuticals (SNDX) stake by 28% in Q3 2026, buying an estimated $162 and bringing the position to 37 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #2203.

Covestor first reported a position in SNDX in Q2 2022 and has held it in 18 quarters since. 126 funds tracked by Wall St. Rank hold SNDX as of Q3 2026.

  • Covestor held 37 shares of Syndax Pharmaceuticals worth $1K as of Q3 2026.
  • Covestor bought 8 Syndax Pharmaceuticals shares in Q3 2026, an estimated $162.
  • Syndax Pharmaceuticals made up ﹤0.01% of Covestor's portfolio in Q3 2026, its #2203 holding.
  • Covestor first reported a position in Syndax Pharmaceuticals in Q2 2022 and has held it in 18 quarters since.
  • 126 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q3 2026.

Based on Covestor's 13F filing for Q3 2026, filed 30 Oct 2026.